Sai Life Sciences Share Price Is Up 55% in 2026: Why PL Capital Sees More Returns and What the Valuation Says
- October 23, 2026
- Posted by: Lakshit Sharma
- Category: News
Sai Life Sciences share price traded at Rs 1,389.60 at about 2:30 PM on 23 Oct 2026, down 0.45%, and is up about 55% from the end of 2025. PL Capital (Prabhudas Lilladher) initiated coverage on 21 Oct with a Buy rating and a target of Rs 1,620, which is about 16.6% above today’s price (my calculation). The stock is still about 18% below its high of Rs 1,697.
Quick Answer
Sai Life Sciences share price is up about 55% in 2026, and PL Capital sees more upside, with a Buy rating and a target of Rs 1,620 issued on 21 Oct. The brokerage expects revenue to grow at a 21% compound rate and net profit at a 26% rate through FY29, helped by growing outsourcing from global pharma firms. The target implies about 55 times forward earnings, so the call depends on growth continuing. This is educational and not a recommendation to buy or sell.
Sai Life Sciences share price has nearly doubled from its February low, and a new Buy call from a brokerage after such a run raises a fair question: how much of the growth is already in the price? The company is a contract research, development and manufacturing organisation, known in the market as a CRDMO, which works for global drug makers.
This article on Sai Life Sciences share price covers today’s move, the PL Capital call, the financials, the valuation, the path of the stock in 2026 and the risks. It is educational and not a recommendation to buy or sell.
Click Here – Get Free Investment Predictions
Sai Life Sciences Share Price Today
| Sai Life Sciences share price: point | Level on 23 Oct 2026 (about 2:30 PM, NSE) |
|---|---|
| Previous close | Rs 1,395.90 |
| Open | Rs 1,391.90 |
| Day high | Rs 1,429.00 |
| Day low | Rs 1,382.90 |
| Last traded price | Rs 1,389.60, down 0.45% |
| Volume so far | About 5.59 lakh shares |
| Market cap | About Rs 29,650 crore |
Sai Life Sciences share price has been quiet on the day, with a range of about 3.3% between the low and the high (my calculation). The new coverage did not trigger a jump, since the weekly close on 19 Oct was Rs 1,389.70, almost the same as today’s level. That suggests the market is weighing the Buy call against a rich valuation.
Track Sai Life Sciences share price and set alerts on the Univest screeners page
PL Capital’s Call on Sai Life Sciences
| Sai Life Sciences share price: PL Capital view (21 Oct 2026) | Detail |
|---|---|
| Rating | Buy, initiation of coverage |
| Target price | Rs 1,620 per share |
| Upside from Rs 1,389.60 (my calculation) | About 16.6% |
| Revenue growth estimate | 21% compound annual growth through FY29 |
| Net profit growth estimate | 26% compound annual growth through FY29 |
| Capex plan | Rs 1,100 crore to Rs 1,300 crore by the end of FY27 |
| Target valuation | About 55 times forward earnings |
| Implied earnings per share at the target (my calculation) | About Rs 29.5 |
The brokerage points to the integrated CRDMO model, where one company supports a drug from early research to commercial manufacturing, and to rising outsourcing by global pharmaceutical firms. The capex is meant to expand capacity and deepen long-term client ties. Whether the Sai Life Sciences share price reaches the Rs 1,620 target price depends on whether the earnings growth in the note actually arrives. A target price is an estimate of where a brokerage thinks a stock could trade in about a year, so it can be revised after each quarter.
Download the Univest iOS App or Univest Android App to get stock alerts and track brokerage calls.
Data note: The PL Capital details are from a report dated 21 Oct 2026. Brokerage targets are opinions, and the note says it is not a buy or sell recommendation.
Sai Life Sciences Financials
| Sai Life Sciences share price: yearly metric (Rs crore) | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 1,494.27 | 1,731.35 | 2,241.62 |
| EBITDA | 314.58 | 442.44 | 672.29 |
| Net profit | 82.81 | 170.13 | 348.91 |
| Diluted EPS (Rs) | 4.53 | 8.61 | 16.43 |
| Capital expenditure | 181.69 | 369.28 | 592.96 |
Revenue rose about 29.5% in FY26 and net profit more than doubled to Rs 348.91 crore, helped by a higher margin and lower interest costs. The EBITDA margin was about 30.0% in FY26 against about 25.6% in FY25 (my calculation). Debt to equity fell to 0.14 as the company raised capital, so the balance sheet is much lighter than it was in FY24.
The Latest Quarter Behind the Sai Life Sciences Share Price
| Sai Life Sciences share price: Q1 FY27 (June 2026) | Figure |
|---|---|
| Revenue | Rs 557.83 crore, up 10.2% YoY and down 9.7% QoQ |
| EBITDA | Rs 151.55 crore, margin about 27.2% (my calculation) |
| Net profit | Rs 73.29 crore, up 21.2% YoY and down 29.7% QoQ |
| Net profit margin | 13.2%, against 17.3% in Q4 FY26 |
The June quarter was softer than the March quarter, and it explains some of the pause in the Sai Life Sciences share price since September. Growth over the previous year is still healthy, but the margin fell by about 4.6 percentage points from the March quarter at the EBITDA level (my calculation). The Q2 FY27 results are the next test, and I have not verified the date.
Sai Life Sciences Share Price: The 2026 Journey
| Sai Life Sciences share price: reference | Level | Change to Rs 1,389.60 (my calculation) |
|---|---|---|
| Close in the last week of Dec 2025 | Rs 896.55 | About 55.0% higher |
| Low in 2026 (week of 2 Feb) | Rs 783.85 | About 77.3% higher |
| High in 2026 (week of 7 Sep) | Rs 1,697.00 | About 18.1% lower |
| Weekly close on 14 Sep | Rs 1,600.50 | About 13.2% lower |
The stock rose from the Rs 780 to Rs 800 zone in February to Rs 1,697 in September and has since slipped about 18% from that high. The 55% gain in the headline is therefore measured from a low base and the stock has already given back part of the run. A Buy call at Rs 1,389.60 compares with the Rs 1,600 level at which the stock traded in mid September, so the new target price is close to where the stock stood six weeks ago.
Sai Life Sciences Share Price Valuation
| Sai Life Sciences share price: valuation measure | Figure |
|---|---|
| Trailing EPS | Rs 17.03 |
| P/E at Rs 1,389.60 | About 81.6 times (my calculation) |
| Industry P/E | 35.77 times |
| Book value per share | Rs 116.93 |
| Price to book at Rs 1,389.60 | About 11.9 times (my calculation) |
| Return on equity | 14.05% |
| Debt to equity | 0.12 |
| Dividend yield | None |
At about 81.6 times trailing earnings the Sai Life Sciences share price is more than twice the industry multiple, and the return on equity of 14.05% is modest for that premium. PL Capital’s target uses about 55 times forward earnings, which is lower than the trailing multiple only because earnings are expected to grow strongly. If growth slows, the premium becomes harder to defend.
Risks Listed for the Sai Life Sciences Share Price
- Execution risk on capex. Large capital projects can strain financial flexibility if they are delayed or run over budget.
- Winning high-value projects. Growth depends on winning big programmes and keeping capacity utilisation high.
- Regulatory inspections. Delays in facility inspections by global health authorities can hold up business.
- Client demand. Outsourcing demand from global pharma can shift with budgets and drug pipelines.
- Competition. Established Indian CRDMO players compete for the same clients.
- Valuation. The P/E of about 81.6 times leaves little room for a miss in growth.
Sai Life Sciences Share Price: Investor Views
| Sai Life Sciences share price: investor type (my reading) | Points to weigh |
|---|---|
| Long-term investor | A fast-growing CRDMO with lower debt can suit a multi-year view, but the valuation needs earnings growth to catch up |
| Short-term trader | The stock needs to hold Rs 1,382.90 and reclaim Rs 1,429 before the pause since September looks over |
| Cautious investor | Waiting for the Q2 FY27 results and margin data gives more evidence than a brokerage target |
This is an educational view and not advice. Brokerage targets can be useful, but they carry assumptions that may not hold.
What to Watch Next on the Sai Life Sciences Share Price
- The Q2 FY27 results and the EBITDA margin against the 27.2% of the June quarter
- The closing price against Rs 1,382.90 and Rs 1,429.00
- Further brokerage coverage after the PL Capital initiation
- Progress on the capex plan and new client programmes
- Any news on regulatory inspections of its facilities
Conclusion
Sai Life Sciences share price is up about 55% in 2026 at Rs 1,389.60, and PL Capital sees a further 16.6% to its Rs 1,620 target on strong CRDMO growth. The business has improved sharply, but the P/E near 82 times and a softer June quarter call for care. Read the filings and decide on your own horizon.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Sai Life Sciences share price target?
Ans. PL Capital (Prabhudas Lilladher) initiated coverage on 21 Oct 2026 with a Buy rating and a target of Rs 1,620. That is about 16.6% above Rs 1,389.60 by my calculation, and it implies about 55 times forward earnings.
How much has the Sai Life Sciences share price gained in 2026?
Ans. It is up about 55% from the close of Rs 896.55 in the last week of Dec 2025 to Rs 1,389.60. It is about 18% below the 2026 high of Rs 1,697 reached in the week of 7 Sep.
What does Sai Life Sciences do?
Ans. It is a contract research, development and manufacturing organisation, or CRDMO, that supports global pharmaceutical companies from early research to commercial manufacturing. Its revenue depends on client programmes and capacity.
What are the Sai Life Sciences financials?
Ans. FY26 revenue was Rs 2,241.62 crore, up about 29.5%, and net profit was Rs 348.91 crore, up about 105%. In the June 2026 quarter, revenue was Rs 557.83 crore and net profit was Rs 73.29 crore.
Is the Sai Life Sciences share price expensive?
Ans. The P/E is about 81.6 times at Rs 1,389.60 against an industry P/E of 35.77, and the price to book is about 11.9 times. The return on equity is 14.05%, so the valuation relies on strong future growth.
What are the risks to the Sai Life Sciences share price?
Ans. Risks include capex execution, winning high-value projects, regulatory inspection delays, shifts in client demand, competition from Indian CRDMO players and a high valuation. Check each against company filings.
When are the Sai Life Sciences Q2 results?
Ans. I have not verified the Q2 FY27 results date, so please check the exchange announcements. The June 2026 quarter showed revenue up 10.2% and net profit up 21.2% from a year earlier.
Is this article investment advice?
Ans. No. It is educational and not a recommendation to buy or sell. Please check the figures against company filings and your own risk profile before you act on anything you read here.